Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 28Leiomyoma 5Endometriosis 3Prostate Adenocarcinoma 2Pregnancy Complications 2Myofibroma 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Hemorrhage 1Pathologic Complete Response 1Neoplasm, Residual 1Neoplasm Metastasis 1Myoma 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-Resistant Prostate Cancer 1Menorrhagia 1

Interventions

Uterine Myomectomy 2relugolix 1elagolix 1Uterine Artery Embolization 1Radiofrequency Ablation 1Norethindrone Acetate 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Estradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Menorrhagia × relugolix × 1 year × Clear all
NCT06671548 2026-02-02

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
120 enrolled

Leiomyoma, Menorrhagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡